Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that Pepaxti® (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK.
November 11, 2022
· 4 min read